News & Updates

Show Multimedia Only

BMI does not affect outcomes with dabigatran-based dual therapy

16 Dec 2020 by

In comparison with warfarin-based triple therapy (warfarin TT), the reduction in bleeding rates with dabigatran-based dual therapy (dabigatran DT) appears consistent across body mass index (BMI) categories in patients with atrial fibrillation (AF) after PCI*, according to a subanalysis of the RE-DUAL PCI** trial.

BMI does not affect outcomes with dabigatran-based dual therapy

16 Dec 2020

AFFIRM-AHF: IV iron cuts risk of HF readmissions

15 Dec 2020 by

Intravenous (IV) iron supplementation with ferric carboxymaltose (FCM) reduces the risk of subsequent hospitalization for heart failure (HF) in iron-deficient patients after an episode of acute HF, shows the AFFIRM-AHF trial presented at the AHA 2020 Meeting.

AFFIRM-AHF: IV iron cuts risk of HF readmissions

15 Dec 2020

Statins come to e of patients with acute large vessel occlusion

15 Dec 2020 by

Initiating statin therapy immediately after onset of large vessel occlusion in acute ischaemic stroke patients proves beneficial, leading to better functional outcome and lower mortality at 90 days, according to data from the RESCUE*‐Japan Registry 2.

Statins come to e of patients with acute large vessel occlusion

15 Dec 2020

News & Updates

Showing Pharmacy articles

Showing

Specialty:

BMI does not affect outcomes with dabigatran-based dual therapy

BMI does not affect outcomes with dabigatran-based dual therapy

AFFIRM-AHF: IV iron cuts risk of HF readmissions

AFFIRM-AHF: IV iron cuts risk of HF readmissions

Statins come to e of patients with acute large vessel occlusion

Statins come to e of patients with acute large vessel occlusion